表紙
市場調查報告書

人類微生物群系的全球市場:成長,趨勢,預測(2019∼2024年)

Human Microbiome Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391460
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
人類微生物群系的全球市場:成長,趨勢,預測(2019∼2024年) Human Microbiome Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 116 Pages
簡介

全球人類微生物群系市場,預計至2024年將以22.60%的年複合成長率擴大。文明病的發病率上升和高齡化,預計帶動市場成長。

本報告提供全球人類微生物群系市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場定義趨勢

  • 市場概要
  • 推動市場的要素
    • 文明病的發病率上升
    • 高齡化
  • 阻礙市場的要素
    • 綜合性研究的不足
    • 嚴格的政府法規
  • 產業的魅力度:波特五力分析

第5章 市場區隔

  • 各用途
    • 治療
    • 診斷
  • 各疾病
    • 肥胖
    • 糖尿病
    • 自體免疫疾病
    • 癌症
    • 腸胃疾病
    • 中樞神經系統疾病
    • 其他
  • 各產品
    • 益生菌
    • 益生元
    • Symboitics
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Enterome Bioscience
    • Yakult
    • DuPont
    • Seres Therapeutics
    • Vithera Pharmaceuticals
    • Second Genome Inc.
    • Synthetic Biologics Inc.
    • Vedanta Biosciences Inc.
    • Osel Inc.
    • Synlogic Inc.

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 50089

Market Overview

The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.

The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.

Scope of the Report

The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.

Key Market Trends

Therapeutic Applications is Expected to hold the Highest Market Share

The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.

The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.

Competitive Landscape

The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Lifestyle-related Diseases
    • 4.2.2 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Comprehensive Research
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Application
    • 5.1.1 Therapeutics
    • 5.1.2 Diagnostics
  • 5.2 Disease
    • 5.2.1 Obesity
    • 5.2.2 Diabetes
    • 5.2.3 Autoimmune Disorder
    • 5.2.4 Cancer
    • 5.2.5 Gastrointestinal Disorders
    • 5.2.6 Central Nervous System Disorders
    • 5.2.7 Other Diseases
  • 5.3 Product
    • 5.3.1 Probiotics
    • 5.3.2 Prebiotics
    • 5.3.3 Symboitics
    • 5.3.4 Other Products
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Enterome Bioscience
    • 6.1.2 Yakult
    • 6.1.3 DuPont
    • 6.1.4 Seres Therapeutics
    • 6.1.5 Vithera Pharmaceuticals
    • 6.1.6 Second Genome Inc.
    • 6.1.7 Synthetic Biologics Inc.
    • 6.1.8 Vedanta Biosciences Inc.
    • 6.1.9 Osel Inc.
    • 6.1.10 Synlogic Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS